Patient Access After FDA Approval: Kaitlyn Sai’s $8K Story

In one of our Pathways in Life Science podcast episodes, Kaitlyn Sai walked us through her insurance fight for an $8,000 a month therapy. The episode is worth your time. This post isn’t a recap. It’s the data sitting in research reports while we were having that conversation, and what the numbers actually say about getting a therapy from approval to a patient’s hand.

Prefer to listen? Catch the episode on Buzzsprout, Apple Podcasts, or Spotify.

The 52 percent number that should be on every commercial team’s wall

IQVIA’s 2024 pharmacy claims analysis of novel active substances launched in 2022 and 2023 found that 52 percent of original specialty drug claims were rejected by the original payer. Only 44 percent of those prescriptions ultimately reached the patient. Across all written prescriptions in the United States, 27 percent never get filled. Commercial plans run at 28 percent abandonment. Medicaid runs at 34 percent.

These are not denial appeal stories. These are prescriptions that disappear in the gap between the prescriber’s pad and the patient’s medicine cabinet. Across the system in 2024, that gap swallowed roughly 96 million new prescriptions.

If you ran a clinical trial with a 52 percent enrollment failure rate, you would never get to phase three. The specialty pharmacy equivalent is happening every week, and most life science commercial dashboards do not track it.

How specialty drug exclusions actually work

The legal background matters here. In the United States, self-funded employer health plans are largely exempt from state insurance regulation under the Employee Retirement Income Security Act. That regulatory carve-out gives plan sponsors freedom to exclude specialty drugs from coverage entirely, often by labeling them as non-essential health benefits.

Many self-funded employers now route excluded patients through what the industry calls alternative funding programs. The patient is funneled to manufacturer patient assistance, foundation grants, or international importation in lieu of plan coverage. The drug spend disappears from the employer’s books. The access gap on the patient side typically stretches six to twelve weeks. For a launch brand, that delay is a commercial risk most market access plans were not built to handle.

A patent cliff that wasn’t

Eltrombopag is a useful case study in this dynamic. The core composition of matter patent expired December 10, 2024. The FDA approved a generic eltrombopag oral suspension in April 2024 and tablet generics in September 2024. By textbook expectations, prices should have collapsed.

In practice, branded Promacta still lists at roughly $6,500 to $7,700 per month in the United States. Generic eltrombopag clears at roughly $4,500 to $6,700 per month. That is a 40 to 50 percent reduction, which is real, and nowhere near the 90 percent erosion typical of small molecules with broad patient populations after generic entry. Specialty drugs do not behave like primary care drugs at patent expiration. Limited indications, specialty pharmacy distribution, and prescriber inertia create commercial moats that generic launches do not always bridge.

What the crowdfunding data is telling us

Dr. Nora Kenworthy’s team at the University of Washington Bothell published an analysis in the American Journal of Public Health that examined more than 437,000 GoFundMe medical campaigns over a five-year window. A 2017 precursor study found that roughly 90 percent of medical crowdfunding campaigns fail to hit their financial goal and that the average campaign raises around 40 percent of the funds requested.

Two takeaways for life science commercial teams. GoFundMe is a misleading safety net because it favors compelling acute stories and fails for chronic specialty drug needs. And every successful medical campaign for a covered indication is a documented failure of the manufacturer’s market access plan.

What this changes for life science commercial strategy

The commercial post-launch playbook needs to expand. A patient services function staffed before launch, foundation referral routing, prior authorization specialists embedded in the field, and live denial dashboards by plan are no longer extras. They are the difference between a clean launch and a slow leak.

The brands we see win at North Star Scientific are the ones who treat market access as a discipline equal to clinical strategy. Across our partner work with GENinCode, AffinityImmuno, and others, the pattern holds. The brands that struggle are usually the ones who outsource access to the payer and hope.

Want the full conversation with Kaitlyn? Hit play above or grab the episode wherever you listen.